ACoP7 - Bellevue, USA 2016

24^th of October 6:00 - 7:30 PM

Title: "Drug Disease Model Resources (DDMoRe) - helping deliver Model-Informed Drug Discovery and Development (MID3)"

Key themes:

• What has been achieved in the IMI DDMoRe project i.e. DDMoRe products.
• How these DDMoRe products can help YOU put MID3 into practice and deliver therapeutic benefit to patients.
• What's next? What's coming with the DDMoRe Foundation? Why is it important to keep going? How can each of us contribute?
• Promoting reproducibility and increased in quality of models, modelling and processes.

Abstract:

1. Model-Informed Drug Discovery and Development (MID) provides a quantitative basis for informed decision making across all stages of drug development. It is an important component in the derivation of a patient's drug-related benefit and risk. A lack of common tools, languages and standards for MID3 limits access to existing information and creates significant gaps in the way knowledge can be exploited within drug development. 
2. In the last 5 and a half years, the DDMoRe project has established a set of standards that allows efficient exchange and reuse of knowledge between stakeholders. The standards have been designed both for model and workflow encoding, and for storage and transfer of models and associated metadata. 
3. This session will showcase the different DDMoRe products based on those new standards - the open, publicly available model repository and interoperability framework. The session will also present the concepts DDMoRe would like to further develop i.e. workflow. Finally, we will introduce the DDMoRe Foundation and how it is set-up to maintain and further enhance the DDMoRe infrastructure and standards to contribute to the quality, efficiency and cost-effectiveness of MID3 and therapeutic use.
4. DDMoRe has now been delivered to the world modeling community. It is no longer a solely "European" project. This session aims also to engage with modelers from the audience and guide anyone who would wish to contribute to the Foundation and to further development of DDMoRe tools and standards. 

 
 
Agenda: 
Brief introduction to IMI, DDMoRe, aims & objectives, deliverables (Presenter: Mike K Smith)

• Project setup: IMI, timescale, objectives.

 
Introduction to the DDMoRe repository (Presenter: Celine Sarr)

• Key Features of the DDMoRe repository
• Demo:  what kinds of models are accessible from the repository
• Model submission and certification process
• Why the DDMoRe repository rather than any other platform e.g. Biomodels, Github (addressing the ISOP questionnaire)

 
Introduction to interoperability (Presenter: Mike K Smith)

• Demo of interoperability
• Benefits of MDL / interoperability: reproducibility
• DDMoRe standards (MDL, PharmML, ProbOnto, SO)

 
Workflow concepts (Presenter: Justin Wilkins)

• What do we mean by workflow?
• Reproducibility of work on a single model (How did you get these results?) versus reproducibility of model building across models (How did I get to the final model?).
• Need for a standard in export / import of workflow information.
• Power of provenance tracking – Link to MID3 concepts re: assumptions, decisions.

 
Future of DDMoRe (Presenter: Mike K Smith)

• How to contribute to development?
• What areas are ripe for contribution? Repository models, extension to new tools, model translation
• The DDMoRe Foundation

 
Questions / General discussion (Moderator: Justin Wilkins)
(Some potential topics for discussion)

• What does "reproducibility" mean to you?
• What would stop you from sharing / publishing a model?
• How would you use models from a model repository?
• What is your expectation about model quality on a repository?
• How do you currently track assumptions and decision making in model and drug development?